Re­cur­sion will take its AI plat­form pub­lic in lat­est IPO fil­ing, while rare heart mu­ta­tion biotech jumps on SPAC train

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

The IPO mar­ket con­tin­ues to churn, with a promi­nent AI drug de­vel­op­er be­com­ing the lat­est biotech to reg­is­ter with the SEC.

Re­cur­sion Phar­ma­ceu­ti­cals filed its S-1 pa­per­work late Mon­day, com­ing about six months af­ter com­plet­ing a $239 mil­lion Se­ries D round and se­cur­ing a deal with Bay­er worth up to $1 bil­lion. The Salt Lake City-based biotech is pen­cil­ing in a $100 mil­lion IPO raise for now, but could have its sights set on a much high­er fig­ure.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER